Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) gapped down before the market opened on Thursday following insider selling activity. The stock had previously closed at $15.86, but opened at $15.36. Recursion Pharmaceuticals shares last traded at $15.76, with a volume of 1,927,818 shares traded.
Specifically, CFO Michael Secora sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $13.63, for a total transaction of $340,750.00. Following the completion of the transaction, the chief financial officer now directly owns 830,413 shares in the company, valued at approximately $11,318,529.19. The sale was disclosed in a document filed with the SEC, which is available through this link. In related news, CFO Michael Secora sold 25,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was sold at an average price of $13.63, for a total transaction of $340,750.00. Following the transaction, the chief financial officer now directly owns 830,413 shares of the company’s stock, valued at $11,318,529.19. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Gibson sold 33,073 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $4.71, for a total value of $155,773.83. Following the completion of the transaction, the chief executive officer now directly owns 953,225 shares in the company, valued at $4,489,689.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 291,627 shares of company stock valued at $2,796,992. Corporate insiders own 19.96% of the company’s stock.
Analyst Upgrades and Downgrades
Several research firms have weighed in on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday. KeyCorp lifted their target price on Recursion Pharmaceuticals from $12.00 to $15.00 in a research report on Thursday, July 13th. Finally, Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Monday, May 22nd. They issued an “equal weight” rating and a $8.00 target price on the stock. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $11.40.
Recursion Pharmaceuticals Price Performance
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last announced its earnings results on Monday, May 8th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.01. Recursion Pharmaceuticals had a negative net margin of 533.45% and a negative return on equity of 57.15%. The business had revenue of $12.13 million during the quarter, compared to the consensus estimate of $15.93 million. On average, equities research analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.42 earnings per share for the current year.
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in RXRX. Accel Wealth Management purchased a new stake in Recursion Pharmaceuticals in the 1st quarter valued at about $41,000. CWM LLC raised its stake in shares of Recursion Pharmaceuticals by 1,888.7% during the 1st quarter. CWM LLC now owns 6,145 shares of the company’s stock worth $41,000 after acquiring an additional 5,836 shares in the last quarter. Daiwa Securities Group Inc. raised its stake in shares of Recursion Pharmaceuticals by 1,029.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 6,903 shares of the company’s stock worth $53,000 after acquiring an additional 6,292 shares in the last quarter. Amundi raised its stake in shares of Recursion Pharmaceuticals by 69.6% during the 4th quarter. Amundi now owns 7,189 shares of the company’s stock worth $57,000 after acquiring an additional 2,949 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Recursion Pharmaceuticals by 453.7% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 8,073 shares of the company’s stock worth $60,000 after acquiring an additional 6,615 shares in the last quarter. 64.79% of the stock is owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers.
Read More
- Five stocks we like better than Recursion Pharmaceuticals
- American Airlines Beats Earnings, Thinking Of Buying?
- Is This The Top For D.R. Horton Stock?
- 3 Undervalued Large-Cap Stocks That Won’t Be for Long
- Johnson & Johnson’s Inflection Point: What it Means for Investors
- Should You Buy the Dip as Tides Change at Taiwan Semiconductor?
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
